Evidence map›Paper›PMID 30872757›Full record

ArticleScientific reports2019

Lyme Disease Patient Trajectories Learned from Electronic Medical Data for Stratification of Disease Risk and Therapeutic Response.

Osamu Ichikawa, Benjamin S Glicksberg, Nicholas Genes, Brian A Kidd, Li Li, Joel T Dudley

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Osamu IchikawaDepartment of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place Box 1498, New York, NY, 10029, USA.
Benjamin S GlicksbergDepartment of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place Box 1498, New York, NY, 10029, USA.
Nicholas GenesDepartment of Emergency Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, 1190 Fifth Avenue Box 1620, New York, NY, 10029, USA.
Brian A KiddDepartment of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place Box 1498, New York, NY, 10029, USA.ORCID 0000-0003-2110-1145
Li LiDepartment of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place Box 1498, New York, NY, 10029, USA. li.li@mssm.edu.
Joel T DudleyDepartment of Genetics and Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place Box 1498, New York, NY, 10029, USA. joel.dudley@mssm.edu.
Icahn School of Medicine at Mount Sinai · USSema4 (United States) · USSumitomo Dainippon Pharma (Japan) · JP

Funding

MSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6M
NCATS NIH HHS UL1 TR001433
6 · The paper itself

Abstract

Lyme disease (LD) is the most common tick-borne illness in the United States. Although appropriate antibiotic treatment is effective for most cases, up to 20% of patients develop post-treatment Lyme disease syndrome (PTLDS). There is an urgent need to improve clinical management of LD using precise understanding of disease and patient stratification. We applied machine-learning to electronic medical records to better characterize the heterogeneity of LD and developed predictive models for identifying medications that are associated with risks of subsequent comorbidities. For broad disease categories, we identified 3, 16, and 17 comorbidities within 2, 5, and 10 years of diagnosis, respectively. At a higher resolution of ICD-9 codes, we identified known associations with LD including chronic pain and cognitive disorders, as well as particular comorbidities on a timescale that matched PTLDS symptomology. We identified 7, 30, and 35 medications associated with risks of these comorbidities within 2, 5, and 10 years, respectively. For instance, the first-line antibiotic doxycycline exhibited a consistently protective association for typical symptoms of LD, including backache. Our approach and findings may suggest new hypotheses for more personalized treatments regimens for LD patients.

Indexed as

AdultAgedAnti-Bacterial AgentsComorbidityDoxycyclineElectronic Health RecordsFemaleFluticasoneHumansLogistic ModelsLyme DiseaseMachine LearningMaleMiddle AgedMometasone FuroateNew York CityAnti-Bacterial AgentsDoxycyclineFluticasoneMometasone Furoate

Identifiers

PMID30872757
PMCPMC6418311
OpenAlexW2921838432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.